Research
Hormonal
GLP-1 receptor agonists provide cardiovascular protection by reducing major adverse cardiac events (MACE), independent of substantial glucose lowering, through mechanisms including improved endothelial function and reduced inflammation.
GLP-1 medications offer significant cardiovascular protection, reducing the risk of heart attack, stroke, and cardiovascular death. This benefit exists even in non-diabetic obese patients, likely due to improved blood vessel function and reduced inflammation, not just weight loss or blood sugar control.
StrongSupportsVERY_HIGH confidence
This result suggests that semaglutide has cardioprotective effect independent of any substantial glucose lowering properties. These include not only effects of weight loss, but also improvements in endothelial function, reductions in low-grade inflammation (evidenced by a significant decrease in high-sensitivity C-reactive protein levels), and potential plaque stabilization [73].
Why this rating
Supported by multiple large-scale clinical trials (LEADER, SUSTAIN-6, SELECT) and meta-analyses.
Source
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Jang Won Son et al. · Endocrinology and Metabolism · 2024
DOI 10.3803/enm.2024.1940
narrative_reviewCited 20×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide produce significant weight loss and improve cardiovascular outcomes by acting as incretin mimetics that target G-protein-coupled receptors to regulate body fat and energy balance.Strong
- Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and other comparators in patients with type 2 diabetes and obesity.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →